Thorax 1999;54:20-26 ( January )

24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids

Andrew M Wilson, Brian J Lipworth

Department of Clinical Pharmacology and Therapeutics and Department of Respiratory Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK

Correspondence to: Professor B J Lipworth.

Received 5 June 1998; Returned to authors 17 August 1998; Revised version received 1 September 1998; Accepted for publication 16 September 1998

BACKGROUNDAs both rhinitis and asthma are allergic conditions, they frequently occur together. The objective of this study was to assess the diurnal adrenocortical activity in asthmatics receiving inhaled (inh) and intranasal (n) formulations of two different corticosteroids, fluticasone propionate (FP) and triamcinolone acetonide (TAA), both given at clinically recommended doses.
METHODSTwelve stable moderately severe asthmatic subjects of mean age 23.9 years and mean forced expiratory volume in one second (FEV₁) 84% predicted were recruited into a randomised placebo (PL) controlled two-way crossover study comparing nPL + inhPL, nPL + inhFP (880 µg bid), and nFP (200 µg once daily) + inhFP (880 µg bid) with nPL + inhPL, nPL + inhTAA (800 µg bid) and nTAA (220 µg once daily) + inhTAA (800 µg bid), each given for five days with a 10 day washout period. Twenty four hour integrated and fractionated (overnight, 08.00 hours, daytime) serum cortisol levels and urinary cortisol/creatinine excretion were measured.
RESULTSFor 24 hour and fractionated serum cortisol levels and corrected urinary cortisol/creatinine excretion there were significant (p<0.05) differences between all active treatments and placebo. For 24 hour integrated serum cortisol levels the ratio between inhaled TAA and FP was 2.3 fold (95% CI 1.2 to 4.3), and for 24 hour urinary cortisol/creatinine excretion the ratio was two-fold (95% CI 1.2 to 3.4). For 24 hour urinary cortisol excretion, with all active treatments, individual abnormal low values of <40 nmol (<14.4 µg) occurred in 17/24 with FP compared with 4/24 with TAA (p<0.0005). The 24 hour serum cortisol profile was flattened by FP but not with TAA. The addition of nasal corticosteroid did not produce further significant suppression of mean cortisol values, although with intranasal FP there were three more abnormal values for 24 hour urinary cortisol excretion than with inhaled FP alone.
CONCLUSIONSBoth inhaled FP and TAA caused significant suppression of adrenocortical activity which was twice as great with FP, the latter being associated with significantly more individual abnormal values and loss of the normal diurnal circadian rhythm. Fractionated serum cortisol levels and urinary cortisol/creatinine excretion were as sensitive as the respective integrated 24 hour measurements. Although the addition of intranasal formulations did not produce further significant suppression of mean values, there were more individual abnormal cortisol values associated with the addition of intranasal FP.

Keywords: adrenal suppression; asthma; corticosteroids

---

© 1999 by Thorax
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Nathan, R. A., Yancey, S. W., Waitkus-Edwards, K., Prillaman, B. A., Stauffer, J. L., Philpot, E., Dorinsky, P. M., Nelson, H. S. (2005). Fluticasone Propionate Nasal Spray Is Superior to Montelukast for Allergic Rhinitis While Neither Affects Overall Asthma Control. Chest 128: 1910-1920 [Abstract] [Full Text]  
• Szefler, S., Rohatagi, S., Williams, J., Lloyd, M., Kundu, S., Banerji, D. (2005). Ciclesonide, a Novel Inhaled Steroid, Does Not Affect Hypothalamic-Pituitary-Adrenal Axis Function in Patients With Moderate-to-Severe Persistent Asthma. Chest 128: 1104-1114 [Abstract] [Full Text]  
• Chrousos, G. P., Ghaly, L., Shedden, A., Iezzoni, D. G., Harris, A. G. (2005). Effects of Mometasone Furoate Dry Powder Inhaler and Beclomethasone Dipropionate Hydrofluoroalkane and Chlorofluorocarbon on the Hypothalamic-Pituitary-Adrenal Axis in Asthmatic Subjects. Chest 128: 70-77 [Abstract] [Full Text]  
• Fardon, T. C., Lee, D. K. C., Haggart, K., McFarlane, L. C., Lipworth, B. J. (2004). Adrenal Suppression with Dry Powder Formulations of Fluticasone Propionate and Mometasone Furoate. Am. J. Respir. Crit. Care Med. 170: 960-966 [Abstract] [Full Text]  
• Hermann, R., Locher, M., Siebert-Weigel, M., LaVallee, N., Derendorf, H., Hochhaus, G. (2004). Intranasal Loteprednol Etabonate in Healthy Male Subjects: Pharmacokinetics and Effects on Endogenous Cortisol. J Clin Pharmacol 44: 510-519 [Abstract] [Full Text]  
• Todd, G R G (2003). Adrenal crisis due to inhaled steroids is underestimated. Arch. Dis. Child. 88: 554-555 [Full Text]  
• Fink, R. S., Pierre, L. N., Daley-Yates, P. T., Richards, D. H., Gibson, A., Honour, J. W. (2002). Hypothalamic-Pituitary-Adrenal Axis Function after Inhaled Corticosteroids: Unreliability of Urinary Free Cortisol Estimation. J. Clin. Endocrinol. Metab. 87: 4541-4546 [Abstract] [Full Text]  
• Currie, G P, Fowler, S J, Wilson, A M, Sims, E J, Orr, L C, Lipworth, B J (2002). Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax 57: 865-868 [Abstract] [Full Text]  
• Fowler, S. J., Orr, L. C., Sims, E. J., Wilson, A. M., Currie, G. P., McFarlane, L., Lipworth, B. J. (2002). Therapeutic Ratio of Hydrofluoroalkane and Chlorofluorocarbon Formulations of Fluticasone Propionate*. Chest 122: 618-623 [Abstract] [Full Text]  
• Carlsen, K-H., Gerritsen, J. (2002). Inhaled steroids in children: adrenal suppression and growth impairment. Eur Respir J 19: 985-988 [Full Text]  
• Martin, R. J., Szefler, S. J., Chinchilli, V. M., Kraft, M., Dolovich, M., Boushey, H. A., Cherniack, R. M., Craig, T. J., Drazen, J. M., Fagan, J. K., Fahy, J. V., Fish, J. E., Ford, J. G., Israel, E., Kunselman, S. J., Lazarus, S. C., Lemanske, R. F. Jr., Peters, S. P., Sorkness, C. A. (2002). Systemic Effect Comparisons of Six Inhaled Corticosteroid Preparations. Am. J. Respir. Crit. Care Med. 165: 1377-1383 [Abstract] [Full Text]  
• Dempsey, O. J., Wilson, A. M., Coutie, W. J. R., Lipworth, B. J. (1999). Evaluation of the Effect of a Large Volume Spacer on the Systemic Bioactivity of Fluticasone Propionate Metered-Dose Inhaler. Chest 116: 935-940 [Abstract] [Full Text]  
• Dempsey, O. J, Coutie, W. J R, Wilson, A. M, Williams, P., Lipworth, B. J (1999). Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate. Thorax 54: 614-617 [Abstract] [Full Text]